VI Partners

Morgen is a time management platform that simplifies the scheduling process by integrating multiple calendars and task management tools into a single application. As the complexity of time management increases, Morgen addresses this challenge by offering a holistic solution that allows users to plan, organize, and optimize their schedules effectively. The platform combines various calendar systems and communication channels, enabling users to manage all events, tasks, lists, and reminders in one place. With its native scheduling tool, Morgen helps individuals and teams reduce meeting chaos and streamline their daily activities, making time management more efficient and less fragmented.

Ninox Software GmbH, based in Berlin, Germany, specializes in developing no-code business applications that empower teams to automate backoffice workflows without requiring programming expertise. The platform offers a variety of templates for functions such as customer relationship management, invoicing, project planning, and data synchronization, enabling over 2,800 companies across diverse industries to digitize their business processes efficiently. Ninox distinguishes itself in the rapidly growing market for no- and low-code application platforms by providing an intuitive onboarding experience akin to modern productivity apps while maintaining the flexibility of application creation. This approach facilitates broader adoption of its tools, allowing users to build fully-functional databases and improve productivity significantly.

Picterra SA operates an online platform that automates artificial intelligence (AI) workflows for object detection to extract geo-information. Founded in 2016 and headquartered in Écublens, Switzerland, the company integrates AI with satellite, drone, and aerial data to help users monitor and anticipate environmental changes. Picterra serves various sectors, including aerial imaging and mapping, financial services, insurance, journalism, precision agriculture, real estate, utilities, infrastructure, as well as public organizations and NGOs. The platform is designed to empower users by allowing them to train and customize AI models without requiring programming or deep learning expertise, thus facilitating the extraction of relevant geo-information tailored to their specific needs.

Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.

turicode Inc. develops software as a service (SaaS) platform for document processing. Its software reads and understands documents such as PDFs, scans, and emails. The company’s MINT.extract platform helps companies and their employees to digitize document. It serves legal and tax, financial industry, healthcare, logistics, insurance, and archives industries. turicode Inc. was founded in 2016 and is based in Winterthur, Switzerland.

Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.

Oculis is a clinical-stage biotechnology company dedicated to developing innovative topical treatments for ophthalmic diseases affecting both the anterior and posterior segments of the eye. Founded in 2003 and headquartered in Reykjavik, Iceland, Oculis utilizes a unique drug delivery platform that enhances drug absorption through a novel technique, enabling effective treatment of conditions such as diabetic macular edema, uveitis, chronic dry eye syndrome, glaucoma, and diabetic retinopathy with simple eye drops. This approach allows for non-invasive treatment of diseases at the back of the eye, traditionally requiring more complex methods, while also reducing the frequency of applications needed for anterior eye conditions. Oculis is committed to improving patient outcomes and enhancing the quality of life for individuals with vision-related health issues.

CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.

Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.

HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.

iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.

Smart Valor AG, founded in 2017 and based in Zug, Switzerland, is a blockchain startup focused on creating a decentralized marketplace for tokenized alternative investments. It facilitates the issuance and distribution of investment solutions and banking services, enabling banks to connect directly with a diverse network of investors. The platform offers secure custody for crypto assets and provides accessible, tokenized investments across various sectors, including real estate, currencies, and venture capital. Additionally, Smart Valor integrates services related to compliance and performance tracking within its decentralized framework. By leveraging the Swiss legal framework, the company aims to combine the security of traditional banking with the innovative potential of blockchain technology.

Gamaya SA specializes in farmland analytics solutions aimed at enhancing the efficiency and sustainability of both large industrial farms and small-holder operations. Founded in 2015 and based in Lausanne, Switzerland, the company offers a range of tools tailored to specific crops, including SOYFIT for soybean cultivation and CANEFIT for sugarcane. Their Agronomic Intelligence Platform serves large-scale tobacco growers. By leveraging advanced technologies such as hyperspectral imaging, embedded cameras, and analytical software, Gamaya provides farmers with actionable insights for early detection of diseases, pests, and stress, as well as monitoring growth and optimizing fertilization. This approach enables better decision-making regarding the use of chemicals and fertilizers, ultimately improving yield while minimizing environmental impact.

Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.

Athelas, Inc. develops and manufactures an innovative in-home blood diagnostic device designed to monitor the immune system using just a drop of blood. Founded in 2016 and based in Mountain View, California, the company's portable optical unit analyzes blood cells and generates diagnostic reports. This technology assists healthcare providers in early identification of conditions such as leukemia, infections, and inflammatory diseases, allowing patients to monitor their immunity levels conveniently from home. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

MESA Imaging specializes in the development and production of 3D time-of-flight cameras designed to capture full 3D images at video frame rates. The company utilizes the Time-of-Flight (TOF) principle and incorporates advanced technologies, such as the silo pixel architecture and the SR4000 sensor chip, to enhance distance measurement capabilities. MESA Imaging supplies its innovative camera systems to various sectors, including video gaming, machine vision, automotive, and robotics, thereby contributing to advancements in image-related industries.

Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.

Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

picoDrill SA provides micromachining techniques for production of hole structures in glass and dielectric materials. Its Electrothermal Selffocussing method allows the controlled heating and evaporation of precisely defined volumes in dielectric materials. The company is based in Lausanne, Switzerland.

Lambda Health System SA specializes in the development and commercialization of innovative rehabilitation technology, particularly focusing on a robotic device known as the Lambda Robot. This device is designed to assist patients with locomotor disabilities, facilitating rehabilitation across various fields including neurorehabilitation, orthopedics, and geriatrics. The Lambda Robot allows therapists to perform exercises without the need for patient transfers between different machines, streamlining the rehabilitation process. Additionally, the company offers the Lambda Control Center, a platform that enables physicians to tailor exercises to individual patient needs while monitoring their progress and adjusting training parameters as necessary. The control center also incorporates engaging games and virtual reality applications aimed at addressing cognitive disorders. Founded in 2015 and based in Yverdon-Les-Bains, Switzerland, Lambda Health System emerged as a spin-off from the University of Applied Sciences of Canton de Vaud, focusing on creating cost-effective and user-friendly rehabilitation solutions.

Advanon AG, based in Zurich, Switzerland, operates an online financial services platform that specializes in invoice financing for small and medium-sized enterprises (SMEs). Founded in 2015, the platform allows businesses to pre-finance their invoices, enabling them to access liquidity without the long wait times typically associated with customer payments, which can range from 30 to 120 days. This service provides SMEs with flexible financing options that help strengthen their cash flow and support growth. Advanon is recognized as a financial intermediary and complies with regulatory standards set by the Swiss Financial Market Supervisory Authority (FINMA) under the Anti Money Laundering Act.

Flytrex Aviation, Ltd., founded in 2013 and based in Tel Aviv, Israel, specializes in the development of cloud-connected drones and demand drone delivery technology. The company offers a comprehensive range of products, including drones, black boxes, loggers, and various accessories, which are distributed through a network of dealers both domestically and internationally, as well as online. Flytrex provides a delivery solution designed to be simpler, faster, cheaper, and more environmentally friendly, catering to drone operators, logistics services, and new business setups. Its technology allows for the automated control of drones via a smart dashboard, facilitating deliveries to hard-to-reach areas while minimizing operational and capital costs. Flytrex currently operates in Iceland and the United States as part of the FAA drone pilot program, aiming to enhance the efficiency of logistics and delivery services.

Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.

Inositec AG is a biotechnology company based in Zurich, Switzerland, established in 2015 as a spin-off from ETH Zurich. The company specializes in the development of drug therapies derived from its proprietary Inositune platform, which utilizes inositol phosphate analogs with adjustable properties. Inositec's lead product, INS-5010, is a non-antibiotic therapy designed to target colon infections caused by Clostridium difficile. Additionally, the company addresses soft tissue calcification disorders, focusing on vascular and renal calcification, including orphan indications. By selectively modifying the phosphate groups in inositol phosphate compounds, Inositec aims to create molecules with improved drug-like properties tailored for specific therapeutic applications.

Gamaya SA specializes in farmland analytics solutions aimed at enhancing the efficiency and sustainability of both large industrial farms and small-holder operations. Founded in 2015 and based in Lausanne, Switzerland, the company offers a range of tools tailored to specific crops, including SOYFIT for soybean cultivation and CANEFIT for sugarcane. Their Agronomic Intelligence Platform serves large-scale tobacco growers. By leveraging advanced technologies such as hyperspectral imaging, embedded cameras, and analytical software, Gamaya provides farmers with actionable insights for early detection of diseases, pests, and stress, as well as monitoring growth and optimizing fertilization. This approach enables better decision-making regarding the use of chemicals and fertilizers, ultimately improving yield while minimizing environmental impact.

Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Equippo is a commercial equipment company that specializes in buying and selling used construction equipment through its online marketplace. Founded in 2014 and headquartered in Zug, Switzerland, the company connects manufacturers, dealers, leasing companies, and other trusted sellers with buyers worldwide, including regions such as South America, Russia, and Poland. Equippo's platform simplifies the process by offering services such as machine inspection, payment management, shipping, trucking, and customs clearance. A notable feature of its service is the Equippo final price calculation engine, which incorporates tariffs, transport, and logistics specific to the buyer's region, making international transactions more straightforward. With a team that can communicate in over nine languages, Equippo aims to facilitate transparent trading in the heavy equipment sector.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

L.E.S.S. designs and manufactures thinner, brighter, more uniform technical lighting systems. Thanks to our innovative approach, our aim is to deliver our customer with lighting systems that provide both intense and uniform light within a small form factor.

UniKey Technologies, Inc. is a company that specializes in access control solutions, offering a platform that transforms smartphones into universal electronic keys. Founded in 2010 and based in Winter Park, Florida, the company provides a smart lock system that includes touch-to-open technology, allowing users to unlock doors without removing their smartphones from pockets or purses. UniKey's platform features advanced intelligence that determines whether an authorized user is present before granting access, enhancing security and preventing unauthorized entry. The company collaborates with lock manufacturers, including Kwikset and Weiser, to develop integrated smart lock solutions like Kevo. Additionally, UniKey offers a cloud-based lock management system tailored for multifamily properties and commercial businesses, which simplifies key management and access control across various applications, including residential, hospitality, and automotive sectors.

Genkyotex SA is a biopharmaceutical company based in Labège, France, focusing on the development of innovative oral small molecule therapies that selectively inhibit NOX enzymes implicated in various disease processes. The company's lead candidate, GKT831, is a NOX1 and NOX4 inhibitor undergoing Phase II clinical trials for primary biliary cholangitis, a fibrotic orphan disease, and type 1 diabetes with kidney complications. In addition, Genkyotex is advancing GKT771, a preclinical NOX1 inhibitor aimed at addressing pain processing and inflammation. The company also holds a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for developing multivalent combination vaccines against infectious diseases. Genkyotex's technology is designed to treat oxygen-radical mediated acute and chronic diseases, offering improved specificity and safety compared to existing antioxidant therapies, and targets cardiovascular, metabolic, and neurodegenerative conditions. Founded in 2006, Genkyotex is committed to enhancing patient outcomes through its research and development initiatives.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Sonic Emotion AG, founded in 2002 and headquartered in Zurich, Switzerland, specializes in advanced audio solutions that create immersive sound experiences. The company's flagship technology, Sonic Emotion Absolute 3D, enables natural 3D sound reproduction using sound field control from as few as two channels, allowing for compact audio setups suitable for a variety of environments. Sonic Emotion AG caters to diverse markets, providing audio solutions for 3D cinemas, events, trade fairs, museums, theme parks, and dance shows. Additionally, the company offers audio simulation services, OEM licensing solutions, and a sound enhancement application named Headquake for Apple i-device products. With research facilities in France and sales offices across Asia, including China, Hong Kong, Taiwan, and Japan, Sonic Emotion AG is positioned to deliver cutting-edge audio technology globally.

Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

Windeln.de operates as an online retailer specializing in products for babies, toddlers, children, and young mothers, serving markets in Germany, Austria, Switzerland, the Czech Republic, Spain, and China. The company offers a diverse range of products, including diapers, baby food, clothing, toys, strollers, child car seats, and baby monitors, as well as children's furniture. Additionally, it provides items for older children and parents, encompassing dietary supplements and cosmetics. Windeln.de's business is structured into segments that include a German shop, international shops, and shopping clubs, catering to a broad customer base across Europe and China.

Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

MerLion Pharmaceuticals GmbH a pharmaceutical company, develops antibacterial drugs and biological products. The company offers finafloxacin, a fluoroquinolone antibiotic for the treatment of infection. The company was founded in 2008 and is based in Berlin, Germany. As of August 21, 2006, MerLion Pharmaceuticals GmbH operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.

SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.

SilentSoft SA, founded in 2000 and headquartered in Morges, Switzerland, specializes in telemetry solutions that facilitate automated real-time communication between connected devices. The company offers a range of products, including StockView, a stock optimization solution for energy distributors, property managers, and end customers, and IndexView, designed for energy efficiency in properties. SilentSoft also provides monitoring devices for tanks and meters, enabling clients to receive real-time data and improve operational efficiency by reducing emergency deliveries and lowering carbon emissions. With additional offices in Meudon, France, and Willstätt, Germany, SilentSoft serves a diverse clientele across European countries, positioning itself as a key player in the Machine to Machine (M2M) industry.

CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.

Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.

Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.

Mobileye is a global leader in developing computer vision and machine learning technologies for advanced driver assistance systems (ADAS) and autonomous driving. Founded in 1999, the company aims to enhance road safety and reduce traffic congestion through its innovative vision-safety technology. With a team of over 1,700 employees, Mobileye has created a range of software products that operate on its proprietary EyeQ® computer chips. The company is a prominent supplier of ADAS software, collaborating with more than 25 major automakers. Mobileye's technology has evolved to encompass the essential components of autonomous driving, including sensing, mapping, and driving policy. It is actively engaged in developing production-ready fully autonomous vehicles in partnership with leading companies. Additionally, Mobileye is working on launching a commercial Mobility-as-a-Service offering, with initial plans set for Tel Aviv. Its comprehensive portfolio of software and hardware solutions positions Mobileye at the forefront of the future of transportation.

Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.

Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland. Dr. Christophe Bonny, CEO and co-founder, is a renowned molecular biologist with over a decade's research expertise on intracellular peptides and signalling.

Covalys Biosciences AG engages in the development and production of tools for protein research. It also provides protein labeling products. The company was founded in 2002 and is based in Witterswil, Switzerland.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.

Neocutis is a manufacturer of cosmeceutical products focused on skincare solutions that promote healthy and youthful skin. The company develops innovative, physician-dispensed products utilizing advanced technology platforms rooted in scientific research. Neocutis offers a range of topical preparations that address various skincare concerns, including the signs of aging, discoloration, oxidative stress, skin redness, and dryness. Additionally, the company provides specialized products for scarless wound healing and dermatological and gynecological infections, enhancing skin texture and overall appearance. Through its commitment to quality and innovation, Neocutis aims to be a trusted leader in the skincare industry.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Avalon Photonics produces world-class VCSELs (vertical cavity surface emitting lasers) for datacom, sensing, and measurement markets. These devices are enabling volume applications due to their exceptional performance, lower power consumption, and volume cost reduction.Avalon also produces unique, patent-protected, single-spatial-mode VCSELs with unsurpassed specifications required for many sensing and measurement applications. Avalon’s ISO 9001 production line achieves high quality, exceptional uniformity, and telecom-grade reliability devices. VCSELs can be provided from bare die up to fully packaged units with temperature control and fiber pigtailing.